Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad, Luminex to Commercialize Protein System

NEW YORK, Dec 12 - Bio-Rad Laboratories and Luminex said Tuesday they had entered into an agreement to jointly commercialize a system for drug discovery applications based on Luminex's LabMAP technology.

Bio-Rad has incorporated Luminex's microsphere-based assay technology and reader into its Bio-Plex Protein Array System. The new product, which will be available in the first quarter of 2001, is the outcome of a two-year collaboration between the companies.

Financial terms of the deal and the collaborative marketing arrangement were not disclosed.

The system, which combines a Luminex analyzer, Bio-Rad’s software, and reagent kits, is designed to help researchers in the life sciences market to easily extract more data from small samples.

Luminex's system is designed to perform up to 100 assays simultaneously on a single drop of fluid, with the capability for both medium- and high-throughput assay applications.

" The hallmark of Bio-Rad Laboratories' integrated Bio-Plex system is that it comes equipped with distinctive improvements in application software and optimized assay kit formulation," Norman Schwartz, vice president of Bio-Rad's life science group, said in a statement.

" These features significantly increase the utility and ease-of-use for researchers and broaden the appeal of the extremely powerful Luminex platform," he said.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.